Expression level and prognostic potential of beta-catenin–interacting protein in acute myeloid leukemia

• Published in: Medicine (Baltimore) Vol. 101; no. 33; p. e30022
• Main Authors: Han, Hui, Zhu, Baofang, Xie, Jinye, Huang, Yunxiu, Geng, Yiyun, Chen, Kang, Wang, Weijia
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 19-08-2022
• Subjects: Adaptor Proteins, Signal Transducing - genetics; beta Catenin - metabolism; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Observational Study; Prognosis
• ISSN: 1536-5964; 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000030022

Inhibitor of beta-catenin and TCF (
ICAT
) is a key protein in the Wnt-β-catenin signaling pathway. However, its role in acute myeloid leukemia (AML) remains unknown. In this study, we evaluated its expression level as well as its prognostic value in AML patients. A total of 72 patients with AML and 30 control subjects were enrolled in this study during the period of January 2017 and December 2019 at Zhongshan Hospital of SunYat-sen University.
ICAT
and
β-catenin
expression levels in peripheral blood were determined via enzyme-linked immunosorbent assays.
ICAT
levels in AML patients were significantly lower and
β-catenin
levels were higher than those of the control group. After the first course of standard chemotherapy, the concentration of
ICAT
in the partial remission group (93.79 ng/mL) was significantly higher than that in the initial diagnosis group (49.38 ng/mL) and the no response group (39.94 ng/mL). AML subtypes had lower
ICAT
expression levels than controls, and
ICAT
levels were significantly correlated with body mass index, bone marrow/peripheral blood blast cell proportions, and white blood cell and red blood cell counts at initial diagnosis. Furthermore, low
ICAT
expression was found to be associated with poor disease-free survival and overall survival in AML.
ICAT
is closely associated with AML progression and can be used as an indicator to monitor AML treatment efficacy.